Recently, the coronavirus recombinant protein vaccine, jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifei LongKema Biopharmaceutical Co.
The recombinant protein vaccine is prepared into a vaccine by expressing purified pathogen antigenic protein in engineering cells through genetic engineering.
Unlike the adenovirus vector vaccines and inactivated vaccines that have previously been approved for clinical trials, this is a new coronavirus vaccine developed by a new technology route.
The vaccine was developed by Gao Fu's team and Yan Jinghua's team at the Institute of Microbiology, Chinese Academy of Sciences.
The results of the preclinical rhesus protection test showed that the vaccine immunization can induce the production of high-level neutralizing antibodies, which has an obvious protective effect.
The current Phase I clinical trial will focus on testing the tolerability and safety of the vaccine in humans.
According to the vaccine development team, the vaccine can be industrially produced through engineered cell lines and has strong accessibility. There is still a long way to go from human clinical trials to the final use of the vaccine, and there is still a long way to go.
CAS Institute of Microbiology has long been committed to basic research on the molecular epidemiology, cross-species transmission of viruses of animal origin and structural biology of pathogens of emerging infectious diseases, and has accumulated many years of research in the field of coronaviruses.
Special Report: Fighting The New Coronavirus
